MannKind (MNKD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating on the stock and has a $11.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Yun Zhong has given his Buy rating due to a combination of factors that highlight the potential of MannKind’s inhaled insulin product, Afrezza. The recent clinical data from the INHALE-3 and INHALE-1 studies have shown promising results in adult patients, suggesting that Afrezza could play a significant role in the diabetes treatment paradigm.
Furthermore, the market adoption of Afrezza is expected to be positively impacted by these findings, as they demonstrate its effectiveness and potential benefits over traditional insulin therapies. Additionally, there is optimism about Afrezza’s prospects in reaching broader patient populations, which could further enhance its market presence and drive growth for MannKind. These factors collectively support Yun Zhong’s positive outlook and Buy rating for MannKind’s stock.
In another report released on May 8, Leerink Partners also reiterated a Buy rating on the stock with a $9.00 price target.